SLC5A2 and heart failure: This review has, for the first time to our knowledge, compared the efficacies of SGLT2 inhibitors and MRAs using RCTs, hence filling the knowledge gap that exists in the long-term benefits of initiating SGLT2 inhibitors and MRAs in heart failure and a head-to-head comparison between the two classes of drugs.